Park brings over 20 years of industry experience to expand innovation and drive brand partner growth ROMEOVILLE, Ill., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN) a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it has appointed Yoolie Park as Vice President of Brand Partnerships. In this role, Park will lead strategic relationships with emerging and established beauty brands, expanding Solésence’s ability to delive ...

CORSICANA, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced the pricing of an underwritten public offering of 6,250,000 shares of its common stock at a public offering price of $2.40 per share, before deducting underwriting discounts and commissions and offering expenses, for aggregate gross proceeds of approximately $15.0 mill ...

Core Insights - Lifetime Brands, Inc. will release its fourth quarter and full year 2025 financial results on March 12, 2026, before market open [1] - The company will host a conference call at 11:00 a.m. Eastern Time on the same day to discuss the results [1] - The CEO and CFO will participate in the 38th Annual ROTH Conference from March 22-24, 2026, in Laguna Niguel, CA, and will be available for meetings with investors [4] Company Overview - Lifetime Brands is a leading global designer, developer, and marketer of a wide range of branded consumer products used in the home [5] - The company markets products under well-known kitchenware brands such as Farberware®, KitchenAid®, and Sabatier®, as well as respected tableware and giftware brands like Mikasa® and Pfaltzgraff® [5] - Lifetime Brands also provides exclusive private label products to leading retailers worldwide [5]

Core Insights - Milestone Pharmaceuticals Inc. will present at the TD Cowen 46th Annual Health Care Conference from March 2-4, 2026 [1] - A live webcast of the presentation will be available on March 3 at 9:10 AM EST, with a replay accessible for approximately 90 days [2] Company Overview - Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines for individuals with specific heart conditions [3] - The company's lead product, CARDAMYST™ (etripamil) nasal spray, is an FDA-approved treatment for converting acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults [3] - Etripamil is also under development for treating symptomatic episodic attacks associated with atrial fibrillation with rapid ventricular response (AFib-RVR) [3]

OMA SAVINGS BANK, PLC STOCK EXCHANGE RELEASE 26 FEBRUARY 2026 AT 15.00 P.M. OTHER INFORMATION DISCLOSED TO THE RULES OF THE EXCHANGE The Board of Directors of Oma Savings Bank Plc commences a new plan period of the employee share savings plan PLAN PERIOD 2026-2029, EMPLOYEE SHARE SAVINGS PLAN The Board of Directors of Oma Savings Bank Plc (“Company” or “OmaSp”) has decided to continue the employee share savings plan (“ESSP”) established in February 2024. The details of the new plan period correspond to the ...

Malaysia, Kuala Lumpur, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Megan Holdings Limited (Nasdaq: MGN) (the “Company” or “Megan”), a Malaysia-based company principally engaged in the development, construction, and maintenance of aquaculture farms and related works, today announced the pricing of its follow-on offering (the “Offering”) of 20,750,000 Class A ordinary shares, par value US$0.0001 per share, at an offering price of US$0.40 per share. The Offering is being conducted on a reasonable best-efforts basis. D. ...

Conference call today at 9:00 am ETQ4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024Successfully completed the acquisition of scPharmaceuticals Inc. (scPharma)Program updates: Afrezza pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) ...

REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fu ...

Core Insights - authID has been selected by a U.S. point-of-sale lending and payment financing platform to enhance its identity verification processes, addressing the rising threat of identity fraud in consumer retail financing [1][2] Industry Context - The selection of authID highlights the increasing demand for biometric identity assurance in the consumer finance sector as fintech platforms face challenges from organized fraud and account takeover attacks that traditional verification methods cannot effectively mitigate [2][4] - In 2024, total U.S. payments fraud losses reached $12.5 billion, with Buy Now Pay Later (BNPL) transactions accounting for 15% of all purchases, indicating a significant risk in this area [5] Company Solutions - To combat fraud, the lender will implement authID Proof™ for identity verification using government-issued IDs during onboarding and authID Verified™ for biometric authentication during account access and high-risk transactions [6] - The platform aims to detect and prevent duplicate and fraudulent applications at onboarding, secure accounts against takeover, and maintain a seamless experience for legitimate users [10] Competitive Advantage - authID's biometric identity verification offers a competitive edge in the commoditized point-of-sale lending market by replacing traditional risk scores and vulnerable authentication methods with deterministic biometric proof, enhancing fraud defenses and customer satisfaction [9] - The company's patented PrivacyKey™ architecture ensures compliance with privacy laws while providing an audit trail based on verified biometrics, further solidifying its market position [8][12] Market Potential - The deployment of authID's solutions is expected to address the high-growth, multi-billion dollar fintech market by verifying the identity of users with industry-leading biometric accuracy in under a second [8][11]

FORT WAYNE, Ind., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vera Bradley, Inc. (Nasdaq: VRA) (the “Company”) today announced that it plans to report results for the fourth quarter and fiscal year ending January 31, 2026 at 8:00 a.m. Eastern Time on Thursday, March 12, 2026. The Company will host a conference call to discuss its financial results at 8:30 a.m. Eastern Time that same day. A live webcast of the conference call will be available on the Company’s website; Investor Relations | Vera Bradley Designs Inc. A ...